Checkpoint Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CKPT research report →
Range $4.1 – $4.1
Price Chart
About the company
Checkpoint Therapeutics, Inc. is a clinical-stage company specializing in immunotherapy and targeted oncology. Its mission involves discovering, advancing, and bringing to market innovative therapeutic solutions for individuals battling solid tumor cancers.
- CEO
- James F. Oliviero III,
- IPO
- 2016
- Employees
- 24
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on CKPT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $367.72M
- P/E
- -3.00
- Fwd P/E
- 3.77
- PEG
- 0.00
- P/S
- 8968.86
- P/B
- -13.39
- EV/EBITDA
- -6.43
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -137009.76%
- Net Margin
- -137170.73%
- ROE
- 438.14%
- ROIC
- 444.94%
Latest fiscal year · YoY change
- Revenue
- $41.00K-60.2%
- Gross Profit
- $41.00K+100.1%
- Op Income
- $-56,174,000
- Net Income
- $-56,240,000-8.5%
- EPS
- $-1.42+48.7%
- OCF Growth
- +34.6%
- FCF Growth
- +34.6%
- 52W High
- $4.50
- 52W Low
- $1.80
- 50D MA
- $4.09
- 200D MA
- $3.33
- Beta
- 1.14
- RSI (14)
- 79
- Avg Volume
- 3.08M
No earnings-call transcripts are available for CKPT yet.
- Free Float
- 77.0%
- Shares Outstanding
- 86.32M
- Float Shares
- 66.45M
of shares held by institutions
74 13F filers
Buy/sell ratio 0.80. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 202.86K | ▲ 37.42K |
| Lindbrook Capital, LLC | 40.00K | ▼ 10.00K |
| Emfo, LLC | 15.71K | 0 |
| Raymond James Financial Services Advisors, Inc. | 10.60K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 29, 25 | Fortress Biotech, Inc. | sell | 100,000 |
| May 30, 25 | Fortress Biotech, Inc. | sell | 6,122,249 |
| May 30, 25 | Fortress Biotech, Inc. | sell | 700,000 |
| May 29, 25 | WEISS MICHAEL S | other | 50,000 |
| May 28, 25 | WEISS MICHAEL S | other | 12,195 |
| May 30, 25 | WEISS MICHAEL S | other | 187,007 |
| May 28, 25 | SALZMAN BARRY M | other | 12,195 |
| May 30, 25 | SALZMAN BARRY M | other | 147,007 |
| May 29, 25 | ROSENWALD LINDSAY A MD | other | 50,000 |
| May 28, 25 | ROSENWALD LINDSAY A MD | other | 12,195 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CKPT coverage
Recent articles, reports, and earnings notes.
No research on CKPT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CKPT report →Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
globenewswire.com · May 13
CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT
businesswire.com · Apr 29
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
globenewswire.com · Mar 28
CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT
businesswire.com · Mar 14
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation into Fairness of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) Buyout Offer and Encourages Investors to Contact the Firm to Discuss Their Legal Rights and Options
globenewswire.com · Mar 13
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma
prnewswire.com · Mar 10
Checkpoint Therapeutics shares pop on acquisition by Sun Pharma
proactiveinvestors.com · Mar 10
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders
businesswire.com · Mar 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.